Stuart A. Aaronson, MD, Icahn School of Medicine at Mount Sinai

Stuart A. Aaronson, MD
Stuart A. Aaronson, MD

Dr. Aaronson's laboratory focuses on cancer gene discovery and function with emphasis on signaling pathways of growth factors including Wnts, PDGF, KGF (FGF-7), and HGF/scatter factor. His laboratory recently identified autocrine Wnt activation in human tumor cells of several tissue types and is studying the relationship of such tumors to stem/progenitor cells of the same tissues in which Wnt signaling helps to maintain the stem/progenitor phenotype. He is also investigating replicative senescence or permanent growth arrest, which appears to be a cell death program distinct from apoptosis, and which must be overcome to attain the immortalization of tumor cells.His laboratory recently uncovered a novel role of p53 in innate antiviral immunity, increasing the diversity of p53 functions that serve to facilitate host pro-survival mechanisms. The laboratory applies cDNA cloning technology and other functional genomic strategies to discover novel targets for cancer intervention.

The Investigator's Annexe Part of The Investigator's Annexe program.



  1. Khan Z, Vijayakumar S, de la Torre TV, Rotolo S, Bafico A. Analysis of endogenous LRP6 function reveals a novel feedback mechanism by which Wnt negatively regulates its receptor. Mol Cell Biol 27:7291-301 (2007).
  2. Goel S1, Chin EN, Fakhraldeen SA, Berry SM, Beebe DJ, Alexander CM.Both LRP5 and LRP6 Receptors Are Required to Respond to Physiological Wnt Ligands in Mammary Epithelial Cells and Fibroblasts. J Biol Chem 287:16454-66 (2012)
  3. van Dinther M, Zhang J, Weidauer SE, Boschert V, Muth EM, Knappik A, de Gorter DJ, van Kasteren PB, Frisch C, Mueller TD, ten Dijke P. Anti-Sclerostin antibody inhibits internalization of Sclerostin and Sclerostin-mediated antagonism of Wnt/LRP6 signaling. PLoS One 8:e62295 (2013)